1. Home
  2. PVLA vs AIRS Comparison

PVLA vs AIRS Comparison

Compare PVLA & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PVLA
  • AIRS
  • Stock Information
  • Founded
  • PVLA 2015
  • AIRS 2012
  • Country
  • PVLA United States
  • AIRS United States
  • Employees
  • PVLA N/A
  • AIRS N/A
  • Industry
  • PVLA Biotechnology: Pharmaceutical Preparations
  • AIRS Medical/Nursing Services
  • Sector
  • PVLA Health Care
  • AIRS Health Care
  • Exchange
  • PVLA Nasdaq
  • AIRS Nasdaq
  • Market Cap
  • PVLA 308.2M
  • AIRS 333.7M
  • IPO Year
  • PVLA N/A
  • AIRS 2021
  • Fundamental
  • Price
  • PVLA $24.36
  • AIRS $1.70
  • Analyst Decision
  • PVLA Strong Buy
  • AIRS Hold
  • Analyst Count
  • PVLA 7
  • AIRS 3
  • Target Price
  • PVLA $44.43
  • AIRS $3.75
  • AVG Volume (30 Days)
  • PVLA 97.9K
  • AIRS 323.9K
  • Earning Date
  • PVLA 05-15-2025
  • AIRS 05-09-2025
  • Dividend Yield
  • PVLA N/A
  • AIRS N/A
  • EPS Growth
  • PVLA N/A
  • AIRS N/A
  • EPS
  • PVLA N/A
  • AIRS N/A
  • Revenue
  • PVLA N/A
  • AIRS $180,350,000.00
  • Revenue This Year
  • PVLA N/A
  • AIRS N/A
  • Revenue Next Year
  • PVLA N/A
  • AIRS $5.54
  • P/E Ratio
  • PVLA N/A
  • AIRS N/A
  • Revenue Growth
  • PVLA N/A
  • AIRS N/A
  • 52 Week Low
  • PVLA $6.20
  • AIRS $1.56
  • 52 Week High
  • PVLA $29.27
  • AIRS $9.20
  • Technical
  • Relative Strength Index (RSI)
  • PVLA N/A
  • AIRS 29.42
  • Support Level
  • PVLA N/A
  • AIRS $1.54
  • Resistance Level
  • PVLA N/A
  • AIRS $2.22
  • Average True Range (ATR)
  • PVLA 0.00
  • AIRS 0.25
  • MACD
  • PVLA 0.00
  • AIRS 0.04
  • Stochastic Oscillator
  • PVLA 0.00
  • AIRS 18.82

About PVLA Palvella Therapeutics Inc. Common Stock

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.

Share on Social Networks: